Fig. 4From: Baseline and recurrent exposure to the standard dose of artemisinin-based combination therapies (ACTs) induces oxidative stress and liver damage in mice (BALB/c)(A) Plasma Aspartate Transaminase (AST) activities (B) Liver Aspartate Transaminase (AST) activities (C) Plasma Alanine Transaminase (ALT) activities (D) Liver Alanine Transaminase (ALT) activities of mice after the 1st, 2nd, 3rd, and 6th exposures to either artemether/lumefantrine (A/L) or artesunate/amodiaquine (A/A) compared to the control. Values are expressed as mean ± SEM (n = 3), and a, b, and c indicate significant differences at p < 0.05, p < 0.01, and p < 0.001, respectively, compared to the corresponding control groupsBack to article page